Five patients received monotherapy with an FGFR inhibitor; two achieved SD ≥ 6 months/PR—both with single alterations on NGS [FGFR2 fusion (biliary tract cancer treated with infigratinib) and FGFR K656E mutation (glioneuronal tumor treated with lenvatinib)]; the other patients, who did not respond, had pathogenic genomic co-alterations in their cancers. The gene discussed is FGFR2; the disease is biliary tract cancer.